Investment Thesis

.

Competitive Moat

against generic competition. Its scale economies allow for efficient production and distribution, while rigorous regulatory compliance enhances barriers to entry for potential competitors. Over the next 5-10 years, this moat is expected to remain durable, though competition from companies like Novo Nordisk and Merck could pose threats, particularly in diabetes and oncology markets.

Growth Engine

Future revenue growth for Eli Lilly is anchored in its expanding portfolio, particularly in diabetes care with products like Trulicity and potential new launches in obesity management. The total addressable market for diabetes drugs is projected to exceed $100 billion by 2027, driven by rising global prevalence. Lilly's strategy includes both organic growth from new product approvals and potential acquisitions that enhance its therapeutic offerings. Currently, the company is gaining market share, particularly in the diabetes and oncology segments, positioning it well for sustained growth.